Bone marrow granulomas possibly associated with amiodarone

Pharmacotherapy

Volumn 20, Issue 7 I, 2000, Pages 855-859

  Yamreudeewong, Weeranuj ^a,b   McIntyre, William W ^b   Sun, Tsieh J ^b   Ranelli, Paul L ^c  

^a UNIVERSITY OF WYOMING SCHOOL OF PHARMACY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF WYOMING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

ADULT; ARTICLE; BONE MARROW BIOPSY; BONE MARROW TOXICITY; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; EYE TOXICITY; GRANULOMA; HEART ATRIUM FIBRILLATION; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MALE; NEUROTOXICITY; PATHOGENESIS; THYROID DISEASE;

EID: 0033947390     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.9.855.35204     Document Type: Article

References (28)

1. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1484;24:129-47.
2. Marcus FI, Fontaine GH, Frank R, Grosgogeat Y. Clinical pharmacology and therapeutic applications of the antiarrhythmic agent, amiodarone. Am Heart J 1981;101:480-93.
3. McEvoy GK, Litvak K, Welsh OH, Snow, EK, eds. Amiodarone. In: AHES drug information 1999. Bethesda, MD: American Society of Health-System Pharmacists, 1999: 1370-82.
4. Zipes DP, Prystowsky EN, Heger JJ. Amiodarone: electrophysiologic actions, pharmacokinetic and clinical effects. J Am Coll Cardiol 1984;3:1059-71.
5. Hamer AW, Mandel WJ, Zaher CA Karagueuzin HS, Peter T. The electrophysiologic basis for the use of amiodarone for treatment of cardiac arrhythmias. Pacing Clin Electrophysiol 1983;6:784-94.
6. Hohnloser S, Klingenheben T, Singh B. Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994;121:529-35.
7. Bauman JL. Class III antiarrhythmic agents: the next wave. Pharmacotherapy 1997;17(2 Pt 2):76S-83.
8. Hohnloser SH. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Am J Cardiol 1997;80(8A):82G-9.
9. Doval HC, Nul DR, Grancelli HO, et al. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-8.
10. Naccarelli GV, Wolbrette DL, Patel HM, Luck JC. Amiodarone: clinical trials. Curr Opin Cardiol 2000;15:64-72.
11. Harre J, Romero J, Rubio JM, Ayala R, Castro-Dorticos J. Amiodarone and "primary" prevention of sudden death: critical review of a decade of clinical trials. Am J Cardiol 1999;83(5B):55D-63.
12. Magro SA, Lawrence EC, Wheeler SH, Krafchek J, Lin HT, Wyndham CR. Amiodarone pulmonary toxicity: prospective evaluation of serial pulmonary function tests. J Am Coll Cardiol 1988;12:781-8.
13. Chang CC, Petrelli M, Tomashefski JF Jr, McCullough AJ. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug. A case report and review of the literature. Arch Pathol Lab Med 1999;123:251-6.
14. Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997;126:63-73.
15. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997;30:791-8.
16. Vrobel TR, Miller PE, Mostow ND, Rakita L. A general overview of amiodarone toxicity: its prevention, detection, and management. Prog Cardiovasc Dis 1989;31:393-426.
17. Collins T. Acute and chronic inflammation. In: Cotran RS, Kumar V, Collins T, eds. Robbins' pathologic basis of disease, 6th ed. Philadelphia: WB Saunders, 1999:50-88.
18. Bhargava V, Farhi DC. Bone marrow granuloma: clinicopathologic findings in 72 cases and review of the literature. Hematol Pathol 1988;2:43-50.
19. Rosenbaum H, Ben-Aric Y, Azzam ZS, Krivoy N. Amiodarone-associated granuloma in bone marrow. Ann Pharmacother 1998;32:60-2.
20. Hostetler KY, Vande Berg J, Aldern KA, Brophy GT. Effect of amiodarone on the phospholipid and lamellar body content of lymphoblasts in vitro and peripheral blood lymphocytes in vivo. Biochem Pharmacol 1991;41:1007-13.
21. Somani P. Basic and clinical pharmacology of amiodarone: relationship of antiarrhythmic effect, dose, and drug concentrations to intracellular inclusion bodies. J Clin Pharmacol 1989,29:405-12.
22. Cozzutto C, Comelli A. Epithelioid granulomata in a nonossifying fibroma. The possible drug-induced mechanism. Virchows Arch A Pathol Anat Histol 1982;397:61-6.
23. Andres E, Kuhnert C, Perrin AE, et al. Sepsis syndrome and bone marrow granulomatosis after intravesical instillation of BCG. Presse Med 1999;28:1753-4.
24. Bodem CR, Hamory BH, Taylor HM, Kleopfer L. Granulomatous bone marrow disease. A review of the literature and clinicopathologic analysis of 58 cases. Medicine 1983;62:372-83.
25. Balkin MS, Buchholtz M, Ortiz J, Green AJ. Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF). Thyroid 1993;3:305-9.
26. Gelfand MS, Yunus F, White FL. Bone marrow granulomas, fever, pancytopenia, and lupus-like syndrome due to tocainide. South Med J 1994;87:839-41.
27. Gill J, Heel RC, Fitton A. Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992;43:69-110.
28. Holt DW, Tucker GT, Jackson PR, Storey GC. Amiodarone pharmacokinetics. Am Heart J 1983;106:840-7